Stifel Nicolaus Healthcare Conference (Infinity Pharmaceuticals) - Sep 7, 2011 - Retaspimycin / Infinity Pharma; Anticipated P2 safety evaluation & clinical activity study initiation in NSCLC patients
Anticipated safety study initiation • Non Small Cell Lung Cancer • None
|